Table 4.
Summary of best overall response to P276-00.
| Response a | N (%) |
|---|---|
| Not Evaluable for Responseb | 2 (15.4%) |
| Best Response | 11 (84.6%) |
| Complete Response | 0 |
| Partial Response | 0 |
| Stable Disease | 2 (15.4%) |
| Progressive Disease | 9 (69.2%) |
a
Responses are according to International Working Group definitions and are further explained in the text.
b
Two cycles of treatment were required to be evaluable for response. Two patients experienced toxicity requiring study discontinuation after only 1 cycle. See text for further details.